Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Juan Carlos Cázarez-Price"'
Autor:
Jeronimo Rafael Rodríguez-Cid, Saul Campos-Gomez, Vanessa García-Montes, Manuel Magallanes-Maciel, Rodrigo Rafael Flores-Mariñelarena, Valeria Michelle Fernández-Garibay, Iván Romarico González-Espinoza, Juan Paulo Ceja-García, Juan Carlos Cázarez-Price, Luis Martínez-Barrera, Leopoldo Barriguete-Parra, Carlos Jose Zuloaga-Fernandez, Roberto Kuri-Exsome, David Suárez-García, Jorge Ignacio Gonzalez-Villanueva, Noé Flores-Anaya, Jose Antonio Acevedo-Delgado, Alma Magdalena Astorga-Ramos, Raquel Gerson-Cwilich, Alberto Villalobos-Prieto, Claudia Rodríguez-Silva, Maria Fernanda Noriega-Iriondo, Leticia Vázquez-Cortés, Eusebio Perales-Rodríguez, Alicia Acosta-Espinoza, Yareni Perez-Lozano, Daniel Capdeville-García, Jorge Arturo Alatorre-Alexander
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 462-470 (2020)
PURPOSEThe LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies.METHODSThis was a retrospecti
Externí odkaz:
https://doaj.org/article/9d217392ca9447fd9047653acf509678
Autor:
Juan Paulo Ceja-García, Manuel Magallanes-Maciel, Noé Flores-Anaya, Valeria Michelle Fernández-Garibay, Daniel Capdeville-García, Jerónimo Rafael Rodríguez-Cid, Carlos Jose Zuloaga-Fernandez, Jorge Ignacio Gonzalez-Villanueva, Vanessa García-Montes, Luis Manuel Martínez-Barrera, Jorge Arturo Alatorre-Alexander, Eusebio Perales-Rodríguez, Saúl Campos-Gómez, Leticia Vázquez-Cortes, Claudia Rodríguez-Silva, Alberto Villalobos-Prieto, Iván Romarico González-Espinoza, Leopoldo Barriguete-Parra, Alicia Acosta-Espinoza, José Antonio Acevedo-Delgado, Juan Carlos Cázarez-Price, David Suárez-García, Roberto Kuri-Exsome, Yareni Perez-Lozano, Raquel Gerson-Cwilich, Rodrigo Rafael Flores-Mariñelarena, Alma Magdalena Astorga-Ramos, Maria Fernanda Noriega-Iriondo
Publikováno v:
JCO Global Oncology
PURPOSE The LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies. METHODS This was a retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e2a1650e71514897659d1ba2a8416d
https://pubmed.ncbi.nlm.nih.gov/32196388
https://pubmed.ncbi.nlm.nih.gov/32196388